Ascendis Pharma A/s Stock News

Ascendis Pharma A/S (ASND) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jan Mikkelsen – President and Chief Executive Officer Scott T. Smith – Senior Vice Presiden

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Shares have lost nearly 40% of their value year to date. I provide a recap of the bullish thesis, which has strengthened considerably with conclusive phase 3 data for TransCon PTH.

New data highlights include:

New data highlights include:

COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candi

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto Novartis AG (NYSE: NVS) said the U.S.

COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candi

ADRs End Mostly Lower; Ascendis Pharma, Infosys Trade Actively Morningstar

The ADRs of Ascendis Pharma (ASND) have recorded the biggest intraday gain since August on Tuesday after Bank of America upgraded the Danish biotech citing “positive” results from a…

Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of it

Following Ascendis Pharma’s (NASDAQ: ASND ) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of its TCP has increased from 60% to 75%, according to BofA Securities. The Ascendis Pharma Analyst: Tazeen Ahmad upgraded the rating for Ascendis Pharma from Neutral to Buy, while raising … Full story available on Benzinga.com

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared

Upgrades For Turquoise Hill Resources Ltd (NYSE: TRQ ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $26.73 and a 52-week-low of $9.75. At the end of the last trading period, Turquoise Hill Resources closed at $26.55. According to BMO Capital, the prior rating for Turquoise Hill Resources Ltd (NYSE: TRQ ) was changed from Underperform to Market Perform. In the fourth quarter, Turquoise Hill Resources showed an EPS of $0.78, compared to $0.79 from the year-ago quarter. The current stock performance of Turquoise Hill Resources shows a 52-week-high of $26.73 and a 52-week-low of $9.75. Moreover, at the end of the last trading period, the closing price was at $26.55. According to DA Davidson, the prior rating for Washington Federal Inc (NASDAQ: WAFD ) was changed from Neutral to Buy. Washington Federal earned $0.71 in the first quarter, compared to $0.51 in the year-ago quarter.

Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. HC Wainwright & Co. lowered Gritstone